Detail akcie American Orient Bio online

Business Summary: American Oriental Bioengineering, Inc. is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Its products in this category include Jinji Series, Cease Enuresis Patch (CE Patch), and Boke Series. Nutraceutical products are intended for the overall well-being. It markets several nutraceutical products in China, which include its soybean peptide based drinks, tablets, powder and instant coffee.
Financial Summary: BRIEF: For the nine months ended 30 September 2013, American Oriental Bioengineering, Inc. revenues decreased 28% to $59.2M. Net loss increased from $23.8M to $54.1M. Revenues reflect Distributiion segment decrease of 8% to $12M. Higher net loss reflects Research and development costs increase of 28% to $6.4M (expense), Other income (expense), net decrease of 71% to $131K (income).